Navigation Links
Oncothyreon reports second quarter 2010 financial results
Date:8/5/2010

KGaA of Darmstadt, Germany, and its U.S. affiliate, EMD Serono, Inc., resumed the worldwide clinical development program for Stimuvax(R) in non-small cell lung cancer (NSCLC), including the Phase 3 START and INSPIRE trials, following a decision by the U.S. Food and Drug Administration (FDA) to partially lift the clinical hold it placed on the Investigational New Drug (IND) application for Stimuvax in March 2010. Treatment of existing patients and enrollment of new patients in START is again underway at most centers. The clinical hold for the Phase 3 STRIDE trial in advanced breast cancer was not lifted by the FDA, and in July Merck Serono decided to close this trial.

PX-866 - Phase 1 clinical trial data for PX-866, an irreversible inhibitor of PI-3 kinase, were presented at the American Society of Clinical Oncology meeting in June. The trial was an open-label, dose escalation study in patients with advanced metastatic cancer of both an intermittent and a continuous dosing schedule, including an expansion cohort at the maximum tolerated dose for each schedule.

PX-866 was well-tolerated in both arms of this trial. The most common adverse events were mild to moderate in severity, and included diarrhea, nausea, vomiting, fatigue and reversible elevation of liver enzymes. There was no significant increase in adverse events noted in patients receiving more than two cycles of treatment in either arm of the trial.

In the continuous dosing arm, 6 of 8 patients evaluable at the time of the presentation (or 75 percent) had stable disease as the best response. In the intermittent dosing arm, 7 out of 45 evaluable patients (or 16 percent) experienced stable disease. Enrollment of additional patients in the continuous dosing arm has now been completed; additional data will be presented at the 22nd EORTC-NCI-AACR sym
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Oncothyreon announces second quarter 2010 financial results conference call
2. Oncothyreon announces presentations at upcoming investor conferences in June
3. Oncothyreon to present at the Rodman & Renshaw Annual Global Investment Conference
4. Oncothyreon reports full year and fourth quarter 2009 financial results
5. Oncothyreon reports first quarter 2010 financial results
6. Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
7. Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement
8. Oncothyreons PX-866 PI-3 kinase inhibitor named among Top 10 most promising oncology products for partnering by Windhover
9. Oncothyreon reports third quarter 2009 financial results & provides product pipeline update
10. Oncothyreon announces webcast of third quarter 2009 financial results conference call
11. Oncothyreon announces appointment of Douglas E. Williams, Ph.D., to board of directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... OR and Hershey, PA (PRWEB) December 19, 2014 ... Pink: BJCT), a leading developer and manufacturer of ... entered into an agreement with Immunomic Therapeutics, Inc. ... Biojector®-2000 needle-free injection device with its LAMP™ vaccine ... an option for an exclusive Worldwide license to ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... 2014 Decision Resources Group finds that the ... 12 percent compound annual growth rate through 2023. This ... and the increasing adoption of dental implants. Growing aesthetic ... also spur demand for dental biomaterials because they can ... treatments. Other key findings from Decision Resources ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3
... BRANFORD, Conn., May 21, 2012  HistoRx, the leader ... proprietary AQUA technology to assessment of messenger RNA ... standardization of protein in tissue specimens; this new ... analysis to quantification of nucleic acids.  ...
... PANAMA CITY, Panama, May 21, 2012 International ... 2012 to discuss the potential use of Oxitec,s genetically modified ... Dengue Fever in Panama. The independent forum was ... Memorial Institute for Health Studies and the University of Panama. ...
... 2012  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... the World Stem Cells & Regenerative Medicine Congress ... 22nd at 12:30 PM. Mr. Garr,s presentation, "Stem ... cellular therapy trial in ALS, its neurogenic small ...
Cached Biology Technology:AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 2AQUA® Technology Uses Extend Beyond Protein: Effective measurement of messenger RNA now demonstrated 3Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 2Expert Meeting Discusses Testing of Oxitec Transgenic Mosquitoes in Panama 3Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London 2
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... have added one more trick to the amazing repertoire ... signals to nerve cells. , Nanotubes, tiny hollow carbon ... hair, are already famed as one of the most ... as steel and one-sixth as dense, able to conduct ...
... 2006 is shaping up as the worst year for California's ... of evolution and ecology at UC Davis. , That's a ... migrated through the Central Valley. But other species have seen ... region altogether. , "It has been the worst spring for ...
... used in Chinese medicine to treat the symptoms of ... reverses some of the pancreatic dysfunctions that underlie the ... Metabolism. The chemical therefore represents a useful starting point ... drug could offer a big advance, the group added, ...
Cached Biology News:Nanotubes used for first time to send signals to nerve cells 2Where have all the butterflies gone? 2Gardenia fruit compound starting point for diabetes therapy 2
Anti-Mouse Ly 6C.2 , Ascites (Clone 5075-3.6) (mouse IgG2b)...
Goat polyclonal to SIAH Interacting Protein ( Abpromise for all tested applications)....
PKC (pSer345), phospho-specific...
Anti-ADAMTS-4, disintegrin-like domain Immunogen: Synthetic peptide - KLH conjugated Available Date: 38569...
Biology Products: